Skip to main content

Drug Interactions between lazertinib and Lumakras

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

sotorasib lazertinib

Applies to: Lumakras (sotorasib) and lazertinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with moderate inducers of CYP450 3A4 may reduce the plasma levels of lazertinib, which is primarily metabolized by the isoenzyme. In a phase 1 study of healthy adult participants, concomitant use of the strong CYP450 3A4 inducer rifampin reduced the peak plasma concentration (Cmax) and systemic exposure (AUC) of lazertinib by 72% and 83%, respectively. Likewise, a pharmacokinetic model predicted that concomitant use with the moderate CYP450 3A4 inducer efavirenz would decrease lazertinib's steady state Cmax and AUC by at least 32% and 44%, respectively. The clinical significance of the effect of moderate CYP450 3A4 inducers has not been established; however, reduced therapeutic efficacy may occur.

MANAGEMENT: According to the manufacturer, due to the potential for reduced therapeutic efficacy, concomitant use of lazertinib with moderate CYP450 3A4 inducers should generally be avoided.
.

Drug and food/lifestyle interactions

Minor

sotorasib food/lifestyle

Applies to: Lumakras (sotorasib)

Information for this minor interaction is available on the professional version.

Minor

lazertinib food/lifestyle

Applies to: lazertinib

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer